ABSTRACT NUMBER: ESOC2026A1708 EDARAVONE DEXBORNEOL AND NINETY DAY FUNCTIONAL RECOVERY IN ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META ANALYSIS
Olivier Uwishema · 2026
Read ABSTRACT NUMBER: ESOC2026A1708 EDARAVONE DEXBORNEOL AND NINETY DAY FUNCTIONAL RECOVERY IN ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META ANALYSIS by Olivier Uwishema (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146994.txt.
Description
Olivier Uwishema, writing alone in 2026, reviews, in a systematic way, a drug pair meant to protect the brain after acute stroke. Most treatments of this kind for ischemic stroke have failed to show steady benefit in care. Edaravone dexborneol, a dual antioxidant and anti-inflammatory agent, has shown good results in recent trials, so a full review was due.
Following PRISMA rules, the review searched four major databases for trials of the drug. The target outcome was functional recovery ninety days after stroke, alongside safety. Pooling the trials tells doctors whether early promise holds up against the full evidence base.
Catalog record
| CREATOR | Olivier Uwishema |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |